Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05641766

Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks

The purpose of this study is to use non-invasive brain imaging methods (MEG and EEG) to characterize the effects of THC on brain activity during learning.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

THC

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

VA Connecticut Healthcare System, Yale School of Medicine

West Haven, Connecticut, 06516, United States

Location contact

Jose Cortes-Briones, PhD

PRINCIPAL_INVESTIGATOR

About this study

The goal of this study is to use multimodal MEG/EEG to gain novel insight into the acute effects of THC on neural noise and its interaction with the fast information processing dynamics of the brain's cognition-related functional neural networks.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cannabis use at least once in the past 12 months
  • No cannabis use during the course of the study confirmed with negative urine toxicology at screening and on each test day
  • Good physical and mental health

Exclusion criteria

  • Cannabis naïve individuals
  • Lifetime or current medical, psychiatric or psychosocial disorders or history that is deemed unsuitable for participation in the study per PI discretion.
  • Positive pregnancy test, lactation, or refusal to practice birth control for the duration of the study and for two weeks following completion
  • Major current or recent stressors
  • Positive urine drug test
  • Contraindication for Magnetic Resonance Imaging
  • Treatment with psychotropic medication as per discretion of the PI
  • IQ less than 80
  • Weight exceeding 166kg
  • Diagnosis of major psychotic or manic disorder in first-degree relatives.

Treatment and study plan

THC

Drug

Participants will receive THC into a rapidly flowing IV infusion.

Placebo

Other

Participants will receive an equivalent amount (about 1-2 ml) of placebo (sterile 190 proof USP ethanol). The placebo does not produce any measurable blood alcohol levels or subjective/behavioral effects.

Primary outcomes

  1. Changes in brain dynamics during the Sternberg Working Memory Task

    Time frame: Baseline and starting at +15 minutes after start of IV THC or placebo administration

    Changes in brain dynamics will be characterized during the Sternberg Working Memory Task where participants are presented with a list of items to memorize, followed by a memory maintenance period during which the subject must maintain the list of items in memory.

Secondary outcomes

  1. Visual Analog Scale (VAS)

    Time frame: Baseline and starting at +15 minutes after start of IV THC or placebo administration

    To confirm the acute effects of THC, feeling states associated with cannabis intoxication will be measured using a self-reported visual analogue scale of four feeling states ("high","anxious","calm and relaxed", and "tired") associated with cannabis effects. Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11mm line from 0=not at all to 100=extremely.

  2. Clinician Administered Dissociative Symptoms Scale (CADSS)

    Time frame: Baseline and starting at +15 minutes after start of IV THC or placebo administration

    To confirm the acute effects of cannabis, perceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-report items and 8 clinician-rated items scored 0=not at all to 4=extremely. The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment.

Study contacts

Contact information is provided by the study sponsor or research team.

Jose Cortes-Briones, PhD

CONTACT

[email protected]

203-903-5711 ext. 5539

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Acronym: THC-MEG

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Dec 8, 2022
Registry last updated
Jun 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.